🇺🇸 FDA
Patent

US 9290574

Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 9290574 (Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
46
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/577